Advaxis 2010 Science Update Conference Call

Thursday, December 16, 2010 at 2:00 p.m. EST

Dial-in: (domestic) 877- 681-3378; (international) 719-325-4750 | Conference ID: 4878858
Playback: (domestic) 888-203-1112; (international) 719-457-0820 | Replay Code: 4878858
Playback available until December 19, 2010 at 5:00 p.m. EST

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, will host a science update investor conference call on Thursday, December 16, 2010 at 2:00 p.m. EST.

The science update will discuss new findings which demonstrate previously undescribed capabilities of Advaxis’ immunotherapy that suppress the immune-protection tumors recruit to defeat immune attacks. These findings were presented at an American Association of Cancer Research meeting last week.

Advaxis has reported in four (4) scientific papers the ability to suppress T-regulatory cells that neutralize immune attacks on tumors. The Company’s new data will show a far broader effect than any disclosed to date. Further research and development of these mechanisms of action are the focus of Advaxis’ Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute at the National Institutes of Health granted October 29, 2010.

"The ability of Advaxis’ Listeria platform technology to remove tumor immuno-protection and stimulate innate and adaptive immunity differentiates it from all other immunotherapies; making it, arguably, the most complete immunotherapeutic technology currently in development,” said Advaxis EVP of Science and Operations Dr. John Rothman.

Immediately following the call, there will be a brief question and answer period. All those interested in participating in the call are welcome to RSVP us at [email protected] by 1:00 p.m. EDT, Thursday, December 16, 2010. The available bridge lines are limited. Please RSVP as soon as practicable. The call will be recorded. A link to the recoding will be posted on our website www.advaxis.com and our corporate portal on facebook on or before Thursday, December 23, 2010.

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, four (4) clinical trials – two (2) in progress and two (2) to be started – and two (2) Cooperative Research and Development Agreements (CRADA) with the National Cancer Institute and the Department of Homeland Security, respectively. The Company conducts direct and strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the University of Pittsburgh and the University of British Columbia.

Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.



CONTACT:

Advaxis, Incorporated
Conrad F. Mir
Executive Director
732-545-1590 (Office)
732-545-1084 (FAX)
[email protected]
or
Advaxis, Incorporated
Diana Moore
Analyst
732-545-1590 (Office)
732-545-1084 (FAX)
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

The analysis found Nexvax2 was no better than placebo at protecting patients from gluten, prompting the Arch-backed biotech to stop the study.

Johns Hopkins scientists found that misfolded alpha-synuclein protein can travel from the gut and drive Parkinson's disease.

The financing sets Sanifit up to take its lead drug through phase 3 while exploring its potential in other progressive vascular calcification disorders.